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OBJECTIVE — We study the effectiveness of the GOAL Lifestyle Implementation Trial at the
36-month follow-up.
RESEARCH DESIGN AND METHODS — Participants (n  352, type 2 diabetes risk
score FINDRISC  16.2  3.3, BMI 32.6  5.0 kg/m
2) received six lifestyle counseling sessions
over 8 months. Measurements were at baseline, 12 months (88.6%), and 36 months (77.0%).
RESULTS — Statisticallysigniﬁcantriskreductionat12monthswasmaintainedat36months
in weight (1.0  5.6 kg), BMI (0.5  2.1 kg/m
2), and serum total cholesterol (0.4  1.1
mmol/l).
CONCLUSIONS — Maintenance of risk reduction in this “real world” trial proves the inter-
vention’s potential for signiﬁcant public health impact.
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T
he Goal Lifestyle Implementation
Trial (1,2) replicated most of the
ﬁndings from the Finnish Diabetes
Prevention Study (DPS) (3,4) in primary
health care settings, demonstrating that
lifestyle counseling can be effective and
feasible in routine care. We report ﬁnd-
ings on sustainability of the results at 3
years.
RESEARCH DESIGN AND
METHODS— This study was devel-
oped and evaluated as a “real world” im-
plementation trial (5). We analyze risk
factor changes from baseline to 3-year
follow-up.
The intervention, with lifestyle
change objectives drawn from the DPS
(3),wasdeliveredassixsessionsoftask-
oriented sociobehavioral group coun-
seling by public health nurses over a
period of 8 months. The protocol in-
cluded no other formal postinterven-
tion contact with the participants,
exceptfollow-upmeasurementsatyears
1 and 3.
A fully detailed description of the
program content, recruitment, partici-
pant characteristics, and measures has
been published previously (1). The
study sample consisted of 352 partici-
pants (age 50–65 years, type 2 diabetes
risk assessed by mean FINDRISC [6]
score 16.2  3.3), of whom 312
(88.6%) attended the measurements at
year 1 and 271 (77.0%) at year 3. Eight
participants responded at year 3 but not
at year 1.
All clinical data at baseline, and
years 1 and 3, were collected by study
nurses. Demographic background data
were self-reported in a baseline ques-
tionnaire. Outcomes included risk fac-
tor changes from baseline to years 1 and
3 (Table 1). Laboratory tests at year 3
were made and analyzed in local health
care centers using the same methodol-
ogy as at year 1 (1).
Differences between respondents and
those lost to follow-up were analyzed
with 
2 tests and independent-samples t
tests, risk factor changes from baseline to
years 1 and 3 with paired-sample t tests,
and the effect of medication use on
cholesterol changes with a repeated-
measures ANOVA. Computations were
performed using the SPSS for Windows
version 15.0.
Principles of the Declaration of Hel-
sinki were followed. The ethics commit-
tee of Pa ¨ija ¨t-Ha ¨me Central Hospital
reviewed the study protocol. All partici-
pants gave their informed consent for the
study.
RESULTS— Reduction in weight and
BMI achieved by year 1 were maintained
also at year 3 (Table 1). Improvement in
blood lipids at year 3 was more pro-
nounced than at year 1, but this was
mainly attributed to the use of lipid-
lowering medication (F  63.135, P 
0.001 for medication use  total choles-
terol interaction). Of the 193 participants
withnormalglucosetoleranceatbaseline,
10.9% had impaired glucose tolerance
(IGT) and 1.6% had diabetes at year 3. Of
the 65 participants who had had IGT at
baseline, 12% had diabetes and 43% had
returned to normal by year 3.
Participants who completed the
study (n  271) differed from partici-
pants who were lost to the 3-year fol-
low-up (n  81) in employment status
(
2  6.447,P  0.040),bybeingmore
often retired (50.0 vs. 39.5%) and less
often unemployed (11.5 vs. 22.4%). At
baseline, the completers also had a
lower mean BMI (32.3  5.0 vs. 33.7 
4.8 kg/m
2, t  2.064, P  0.040) and
waist circumference (104.6  12.3 vs.
107.9  11.9 cm, t  2.105, P 
0.036). At year 1, the differences did
not yield signiﬁcance (31.9  4.9 vs.
33.1 4.7kg/m
2,NS,forBMI;102.7
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CONCLUSIONS — The GOAL Life-
style Implementation Trial was de-
signed to replicate results from efﬁcacy
trials such as the DPS (3,4), under more
“real world” conditions with a more
modest program delivered by existing
health care personnel (1). Previously,
we demonstrated that the model was
reasonably successful in attaining many
of the key lifestyle objectives. This longer-
term follow-up has demonstrated that de-
spite the relatively modest initial risk
reduction(e.g.,weightreductionatyear1
was only 0.8 kg in the GOAL trial com-
pared with 4.5 kg in the DPS [3]), pro-
gram maintenance was quite good.
Between years 1 and 3, an average regain
of 1 kg was found in the DPS, resulting in
a 3.5  5.1 kg weight reduction from
baseline to 3 years (4), whereas in the
GOAL trial, the weight decrease achieved
at year 1 persisted throughout the follow-
up. The same pattern was also evident in
BMI. Improvement in blood lipids from
baseline to 3 years was similar to the DPS.
Conversion rate from IGT to diabetes
(12% at year 3) is moderate compared
with 9% in the intervention and 20% in
thecontrolgroupoftheDPS(4).Further-
more,asigniﬁcantnumberofparticipants
reverted to normal glucose tolerance
(7.8 mmol/l) during the follow-up.
A single group pretest and posttest
study design and use of the DPS ﬁndings
from the same culture as a benchmark of-
fersbeneﬁtsthatwehavediscussedearlier
(1). The unemployed were more likely to
drop out from the study during the
postintervention follow-up, a factor lim-
itingtheconclusionsthatcanbedrawnof
the long-term effectiveness of the inter-
vention in this group of people.
A proportion of participants in any
lifestyle intervention will fail to achieve
change sufﬁcient to signiﬁcantly reduce
clinical risks and will therefore also re-
quire pharmacological treatment. Blood
lipid improvement after the ﬁrst year was
primarily attributable to prescription of
lipid-lowering medication, suggesting
that dyslipidemia was identiﬁed and
could be effectively treated by the health
care among those participants who had
failed to make necessary or sufﬁcient life-
style changes.
Program intensity signiﬁcantly corre-
lates with weight loss (7). In the pub-
lished efﬁcacy trials, it has generally been
greater than in our study, with contacts
extending throughout the follow-up pe-
riod (8,9). Such intensive interventions
are likely limited to particularly high-risk
groups. With the kind of intervention
tested in our study, also those with a
lower risk status could be targeted and
much larger numbers of people reached.
InthePa ¨ija ¨t-Ha ¨meprovince,theprogram
has now been integrated into the regional
health care, where it is by default offered
to all patients with elevated FINDRISC
score (6). With systematic identiﬁcation
and counseling, this “low intensity, high
reach” approach provides a potential for
signiﬁcantly improved population health.
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